Michael Bishop to Clinical Trials as Topic
This is a "connection" page, showing publications Michael Bishop has written about Clinical Trials as Topic.
Connection Strength
0.596
-
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer. 2022 09; 10(9).
Score: 0.136
-
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Adv Ther. 2022 08; 39(8):3678-3695.
Score: 0.134
-
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 12 04; 6(1):137.
Score: 0.105
-
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54.
Score: 0.061
-
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer. 2010 Feb 15; 116(4):852-62.
Score: 0.057
-
Monoclonal antibody therapy. Front Biosci. 2006 May 01; 11:1620-35.
Score: 0.044
-
Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? Curr Hematol Malig Rep. 2010 Oct; 5(4):229-38.
Score: 0.015
-
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46.
Score: 0.015
-
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood. 2009 Nov 12; 114(20):4494-502.
Score: 0.014
-
Immunotherapy for breast cancer. Cancer Chemother Biol Response Modif. 2002; 20:351-69.
Score: 0.008
-
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma. 2000 Mar; 37(1-2):65-70.
Score: 0.007